Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.
Combo Treatment Sans Chemotherapy Effective for Ph+ ALL Elderly miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
The addition of quizartinib to induction and consolidation chemotherapy, followed by single-agent quizartinib for up to 36 cycles, improved survival outcomes vs placebo in patients with FLT3 ITD–mutated, newly diagnosed acute myeloid leukemia.
Quizartinib added to induction and consolidation chemotherapy and continued as a single agent for up to 36 cycles improves the overall survival of adults with FLT3 ITD mutated AML.
Harry P. Erba, MD, PhD, discusses the implications of the FDA approval of quizartinib for the treatment of patients with FLT3-ITD–mutated AML, the background and key findings of the QuANTUM-First study, and how to now navigate between potential treatment options for this patient population.